Clinical Trials

Research

 

Dr. Iram Ahmad, MD, MME

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Jennifer Alyono, MD, MS

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Noel Ayoub, MD, MBA

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Fred M. Baik, MD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Karthik Balakrishnan, MD, MPH, FAAP, FACS

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Nikolas Blevins, MD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Robson Capasso, MD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Michael Chang, MD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Kay W. Chang, MD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Michelle Chen, MD, MHS

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Alan G. Cheng, MD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Edward J. Damrose, MD, FACS

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Seth Davis, MD, FACS

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Vasu Divi, MD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Elizabeth Erickson-DiRenzo, PhD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Andrey Finegersh, MD, PhD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Matthew Fitzgerald, PhD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Pedro Gomes de Oliveira, MD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Stefan Heller, PhD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Katie Hohenberger, MD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Chris Holsinger, MD, FACS

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Peter H. Hwang, MD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Nancy Jiang, MD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Grace Kim, MD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Jennifer Lee, MD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Jake Lee, MD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. William Lewis, MD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Ted Mau, MD, PhD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Uchechukwu Megwalu, MD, MPH

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Kara Meister, MD, FAAP, FACS

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Lloyd Minor, MD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Lindsay Moore, MD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Sam P. Most, MD, FACS

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Eric Nash, MD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Jayakar V. Nayak, MD, PhD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Teresa Nicolson, PhD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Brian Nuyen, MD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Dáibhid Ó Maoiléidigh, PhD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Lisa A. Orloff, MD, FACS, FACE

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Zara Patel, MD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Jon-Paul Pepper, MD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Anthony J. Ricci, PhD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Nathan Reticker-Flynn, PhD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Douglas Sidell, MD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Davud Sirjani, MD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Alyssa Smith, MD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Konstantina M. Stankovic, MD, PhD, FACS

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Heather Starmer, MA CCC-SLP, BCS-S

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Kristen K. Steenerson, MD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. C. Kwang Sung, MD, MS

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. John B. Sunwoo, MD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Tristan Tham, MD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Mai Thy Truong, MD

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials

Dr. Tulio Valdez, MD, MSc

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • procedure: Tumor biopsy
  • procedure: Phlebotomy

Eligibility

Inclusion Criteria:

* Histologically confirmed squamous cell carcinoma of the head and neck sites or non-small cell lung cancer, or relatives of patients with histologically confirmed squamous cell carcinoma of the head and neck.
* Able to sign a Stanford IRB approved consent form

Exclusion criteria:

* Refuse or unable to sign an IRB approved consent form.
* Refuse to be contacted in the future for follow up.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

ALL

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Eyiwunmi Laseinde
I'm interested

Explore Related Trials

All Stanford Trials
Stanford Clinical Trials
Stanford Cancer Institute Clinical Trials